Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA To Consider Critical Path Trial Design Proposals On Case-By-Case Basis

Executive Summary

FDA will generally take a case-by-case approach to considering and accepting development programs using clinical trial designs discussed in its Critical Path opportunities list

You may also be interested in...



Personalized Medicine Is Closer Than You Think, FDA’s Throckmorton Says

Personalized medicine should be adopted as a prospective strategy in drug development rather than primarily serving as a tool to salvage failing drug candidates, participants at FDA's Science Forum suggested

Personalized Medicine Is Closer Than You Think, FDA’s Throckmorton Says

Personalized medicine should be adopted as a prospective strategy in drug development rather than primarily serving as a tool to salvage failing drug candidates, participants at FDA's Science Forum suggested

Use Of Non-Inferiority Trials Could Increase Despite Unclear Guidance

Regulators need to provide greater clarity on non-inferiority clinical trial designs, an Amgen exec said during FDA's 2006 Science Forum

Related Content

UsernamePublicRestriction

Register

PS047064

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel